You are Acinetobacter's WorstNightmare
when you use XACDURO against hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in adults caused by Acinetobacter.
It's the first and only treatment targeting HABP/VABP caused by susceptible isolates, which can include multidrug-resistant strains of Acinetobacter baumannii‑calcoaceticus complex.1,2
Powerful results against HABP/VABP infections caused by Acinetobacter
In the Phase 3 ATTACK noninferiority trial evaluating safety and efficacy of XACDURO vs. colistin for patients with serious infections due to ABC, including CRABC strains, XACDURO demonstrated:
- Improved all-cause mortality rate
- Significantly greater clinical cure rate
ABC=Acinetobacter baumannii-calcoaceticus complex;
CRABC=carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex.
Stay up to date
Receive email updates about XACDURO.
1. Data on File. Innoviva Specialty Therapeutics; 2023. 2. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. Published online May 11, 2023. doi:10.1016/S1473‑3099(23)00184‑6 3. Murray CJL, Ikuta KS, Sharara F, et al. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629‑655. 4. CDC. COVID‑19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2022.